Our findings suggest that among adults with Down syndrome, cerebrovascular disease promotes Alzheimer’s disease-related neurodegeneration indirectly through increasing astrocytosis and tau pathophysiology in the preclinical stages of Alzheimer’s disease and directly and indirectly in the clinical stages of Alzheimer’s disease. The gene discussed is MAPT; the disease is cerebrovascular disorder.